WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  July 23, 2003

                          BECTON, DICKINSON AND COMPANY
             (Exact name of registrant as specified in its charter)

           New Jersey                001-4802                   22-0760120
    (State or other juris-         (Commission             (IRS Employer Iden-
   diction of incorporation)       File Number)            tification Number)

   1 Becton Drive, Franklin Lakes, New Jersey                   07417-1880
    (Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code          (201) 847-6800

         (Former name or former addresses if changed since last report.)

Item 9. Regulation FD Disclosure.

The following statement is being furnished by the Company under the provisions
of Regulation FD:

         BD (Becton, Dickinson and Company) announced on July 23, 2003 that it
         is conducting a voluntary recall in Canada of three lots of BD'TM' Test
         Strips that were manufactured for use with the BD Latitude'TM' Diabetes
         Management System. The distribution of these three lots was limited to
         Canada, and represents a small percentage of total BD'TM' Test Strips
         produced to date.

         The costs anticipated with recalling these three lots are not expected
         to be significant and will be reflected in the Company's third quarter
         results for the period ended June 30, 2003. The sales value of the
         BD'TM' Test Strips being recalled in Canada is approximately U.S.
         $400,000. Total sales of BD'TM' Test Strips in the U.S. and Canada for
         the first half of BD's fiscal year 2003, for use with the BD
         Latitude'TM' Diabetes Management System and the BD Logic'TM' Blood
         Glucose Monitor, were approximately $5 million.

         BD is taking this action following an internal quality review, which
         determined that test strips from these three lots did not meet all of
         BD's quality and performance specifications. The potential issues
         presented by test strips from these lots relate primarily to the
         accuracy of readings at low blood glucose levels, especially for
         asymptomatic hypoglycemic patients. BD has not received any reports of
         serious injury resulting from inaccurate readings from test strips in
         these lots.

         The Company is advising the U.S. Food and Drug Administration (FDA) and
         Health Canada of this corrective action. BD is continuing its quality
         review of its BD'TM' Test Strips, will work with the FDA and Health
         Canada in connection with the issues associated with this announced
         recall and market notification process, and will take any other
         corrective actions that may be required.

         This report may contain certain forward-looking statements (as defined
         under Federal securities laws) regarding BD's performance, including
         future revenues, products and income, or events or developments that BD
         expects to occur or anticipates occurring in the future. All such
         statements are based upon current expectations of BD and involve a
         number of business risks and uncertainties. Actual results could vary
         materially from anticipated results described, implied or projected in
         any forward-looking statement. Factors that could cause actual results
         to vary materially from any forward-looking statement include, but are
         not limited to: competitive factors; pricing and market share
         pressures; uncertainties of litigation; BD's ability to achieve sales
         and earnings forecasts, which are based on sales volume and product mix
         assumptions, to achieve its cost savings objectives, and to achieve
         anticipated synergies and other cost savings in connection with
         acquisitions; changes in regional, national or foreign economic
         conditions; increases in energy costs; fluctuations in costs and
         availability of raw materials and in BD's ability to maintain favorable
         supplier arrangements and relationships; changes in interest or foreign
         currency exchange rates; delays in product introductions; and changes
         in health care or other governmental regulation, as well as other
         factors discussed in this report and in BD's filings with the
         Securities and Exchange Commission. BD does not intend to update any
         forward-looking statements.


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           BECTON, DICKINSON AND COMPANY

                                           By: /s/ Gary DeFazio
                                                   Gary DeFazio
                                                   Assistant Secretary

Date: July 23, 2003

                      STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as..................    'TM'